Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine-Reference-Cited by-同舟云学术

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Published:2018-12-10 Issue:1 Volume:33 Page:61-79
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Hobart Jeremy,Ziemssen Tjalf,Feys Peter,Linnebank Michael,Goodman Andrew D.,Farrell Rachel,Hupperts Raymond,Blight Andrew R.,Englishby Veronica,McNeill Manjit,Chang Ih,Lima Gabriel,Elkins Jacob,

Funder

Biogen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/article/10.1007/s40263-018-0586-5/fulltext.html

Reference49 articles.

1. van Asch P. Impact of mobility impairment in multiple sclerosis 2—patients’ perspectives. Eur Neurol Rev. 2011;6(2):115–20.

2. Sutliff MH. Contribution of impaired mobility to patient burden in multiple sclerosis. Curr Med Res Opin. 2010;26(1):109–19.

3. Heesen C, Bohm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14(7):988–91.

4. European Medicines Agency. Fampyra 10 mg prolonged-release tablets [summary of product characteristics]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002097/WC500109956.pdf. Accessed 22 Aug 2018.

5. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006;111(1):224–59.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reasons Patients With Primary Progressive Multiple Sclerosis Contact Their Specialist Nurses;International Journal of MS Care;2024-01-01

2. Translation and validation of the multiple sclerosis walking scale 12 for the German population – the MSWS-12/D;Health and Quality of Life Outcomes;2023-10-09

3. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system;Frontiers in Pharmacology;2023-09-14

4. Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection;Multiple Sclerosis and Related Disorders;2023-08

5. Investigating the safety of Fampridine in patients with different stages of multiple sclerosis;2023-06-29